Profile data is unavailable for this security.
About the company
Arterra Bioscience SpA is an Italy-based biotechnology company. It focuses on research and development of ingredients and natural solutions. By exploiting the potentialities of living organisms such as bacteria, yeasts, plants and animal cells, the Company develops products and processes that serve as enabling technologies and that find horizontal application in various industrial sectors, such as cosmetics, agriculture and nutraceutics. The Company’s main activities and applications include development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds and the production of high-tech raw materials with application in different industrial fields. The Company collaborates with private companies, universities and research institutes all over the world.
- Revenue in EUR (TTM)3.30m
- Net income in EUR1.08m
- Incorporated--
- Employees30.00
- LocationArterra Bioscience SpAvia Benedetto Brin, 69NAPOLI 80142ItalyITA
- Websitehttps://www.arterrabio.it
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AroCell AB (publ) | 3.82m | -4.78m | 10.60m | -- | -- | 0.8123 | -- | 2.78 | -0.2437 | -0.2437 | 0.1944 | 0.6648 | 0.2325 | 5.82 | 5.63 | -- | -29.14 | -29.25 | -31.00 | -31.37 | 1.88 | -9.85 | -125.33 | -231.19 | 5.16 | -- | 0.00 | -- | 16.37 | 122.92 | -0.5494 | -- | -- | -- |
| Synairgen plc | 0.00 | -9.97m | 11.16m | 36.00 | -- | 0.7438 | -- | -- | -0.0418 | -0.0418 | 0.00 | 0.0629 | 0.00 | -- | -- | 0.00 | -44.55 | -54.01 | -51.06 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
| Medicofarma Biotech SA | 317.79k | -672.60k | 11.29m | -- | -- | 4.87 | -- | 35.52 | -0.0423 | -0.0423 | 0.02 | 0.1459 | 0.0866 | 5.56 | 2.83 | -- | -18.34 | -15.05 | -23.49 | -18.17 | 78.54 | 29.92 | -211.65 | -42.86 | 0.805 | -16.98 | 0.00 | -- | -82.34 | -31.48 | -116.39 | -- | -- | -- |
| Coegin Pharma AB | 0.00 | -2.38m | 11.96m | 0.00 | -- | 10.78 | -- | -- | -2.65 | -2.65 | 0.00 | 0.6403 | 0.00 | -- | -- | -- | -125.24 | -122.02 | -201.53 | -154.70 | -- | -- | -- | -28,466.75 | -- | -170.65 | 0.00 | -- | -- | -- | 20.60 | -- | -- | -- |
| Addex Therapeutics Ltd | 1.44m | -9.26m | 12.06m | 23.00 | -- | -- | -- | 8.39 | -0.1116 | -0.1357 | 0.0166 | -0.014 | 0.2596 | -- | 8.91 | 59,997.39 | -167.14 | -69.05 | -637.08 | -84.19 | -- | -- | -643.81 | -572.59 | -- | -36.25 | -- | -- | 13.99 | -24.47 | 49.26 | -- | -5.45 | -- |
| Bivictrix Therapeutics PLC | 0.00 | -3.02m | 12.72m | 12.00 | -- | 3.03 | -- | -- | -0.0351 | -0.0351 | 0.00 | 0.0429 | 0.00 | -- | -- | 0.00 | -57.64 | -- | -65.12 | -- | -- | -- | -- | -- | -- | -- | 0.069 | -- | -- | -- | -1.92 | -- | -- | -- |
| Biosergen AB | 0.00 | -2.46m | 12.77m | 4.00 | -- | 2.16 | -- | -- | -0.3579 | -0.3579 | 0.00 | 0.2497 | 0.00 | -- | -- | 0.00 | -113.63 | -- | -147.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.25 | -- | -- | -- |
| Ascelia Pharma AB | 0.00 | -7.56m | 13.36m | 13.00 | -- | 2.58 | -- | -- | -2.63 | -2.63 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -65.17 | -- | -78.39 | -- | -- | -- | -- | -- | -- | -- | 0.2302 | -- | -- | -- | 16.72 | -- | -- | -- |
| Arterra Bioscience SpA | 3.30m | 1.08m | 13.45m | 30.00 | 12.44 | 1.25 | 7.93 | 4.07 | 0.1624 | 0.1624 | 0.4985 | 1.62 | 0.263 | 1.18 | -- | -- | 8.57 | 10.57 | 9.44 | 12.30 | 55.03 | 60.57 | 32.57 | 34.31 | 7.47 | -- | -- | -- | -7.28 | 6.36 | -23.89 | 0.6056 | -- | -- |
| Xintela AB | 32.11k | -4.19m | 14.15m | -- | -- | -- | -- | 440.53 | -0.1217 | -0.1217 | 0.0008 | -0.0136 | 0.0193 | -- | 0.0447 | -- | -252.59 | -181.06 | -- | -391.61 | 100.00 | -- | -13,061.54 | -235,894.00 | -- | -49.47 | -- | -- | -- | -45.54 | 18.32 | -- | -61.47 | -- |
| AlzeCure Pharma AB | 0.00 | -3.19m | 14.34m | 11.00 | -- | 9.21 | -- | -- | -0.5685 | -0.5685 | 0.00 | 0.2122 | 0.00 | -- | -- | 0.00 | -92.80 | -52.78 | -115.25 | -57.01 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.91 | -- | -- | -- |
| Vidac Pharma Holding PLC | 0.00 | -1.03m | 14.42m | 4.00 | -- | -- | -- | -- | -0.0196 | -0.0196 | 0.00 | -0.0097 | 0.00 | -- | -- | -- | -562.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Prolight Diagnostics AB (publ) | 0.00 | -11.65m | 14.55m | 16.00 | -- | 1.15 | -- | -- | -0.3953 | -0.3953 | 0.00 | 0.2488 | 0.00 | -- | -- | 0.00 | -64.42 | -- | -84.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -13.84 | -- |
| Active Biotech AB publ | 0.00 | -3.82m | 15.16m | 8.00 | -- | 8.85 | -- | -- | -0.1651 | -0.1651 | 0.00 | 0.0556 | 0.00 | -- | -- | -- | -122.57 | -57.97 | -179.56 | -97.83 | -- | -- | -- | -1,454.61 | -- | -- | 0.1145 | -- | -- | -- | 21.54 | -- | -- | -- |
| Read Gene SA | 2.51m | -337.90k | 15.44m | 11.00 | -- | 15.00 | -- | 6.14 | -0.1551 | -0.1551 | 1.07 | 0.3732 | 0.7606 | 9.91 | 9.55 | -- | -10.22 | -1.06 | -10.58 | -1.31 | 91.56 | 88.41 | -13.44 | -2.42 | 10.10 | -3.45 | 0.00 | -- | 40.14 | 16.00 | -731.53 | -- | -- | -- |
| LungLife AI Inc | 42.37k | -4.99m | 15.79m | 15.00 | -- | 0.5588 | -- | 372.58 | -0.165 | -0.165 | 0.0014 | 0.2412 | 0.0038 | -- | 0.2831 | 2,382.43 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
Data as of Jul 26 2024. Currency figures normalised to Arterra Bioscience SpA's reporting currency: Euro EUR
1.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mediolanum Gestione Fondi SGRpAas of 29 Dec 2023 | 72.00k | 1.08% |
| Lemanik Invest SAas of 30 Jun 2022 | 10.50k | 0.16% |
Data from 31 May 2024 - 28 Jun 2024Source: FactSet Research Systems Inc.
